Vincerx Pharma, Inc.Sales Agreement • March 28th, 2024
We have entered into a sales agreement, dated March 29, 2024 (the “Sales Agreement”), with Leerink Partners LLC (“Leerink Partners”), relating to our common stock, $0.0001 par value per share (“Common Stock”), offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, from time to time we may offer and sell our Common Stock having an aggregate gross sales price of up to $50,000,000 through Leerink Partners, acting as sales agent or principal, pursuant to this prospectus supplement and the accompanying prospectus.
Vincerx Pharma, Inc.Sales Agreement • March 28th, 2024
We have entered into a sales agreement, dated January 21, 2025 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) relating to our common stock, $0.0001 par value per share (“Common Stock”), offered by this prospectus and the accompanying prospectus. In accordance with the terms of the Sales Agreement, from time to time we may offer and sell our Common Stock having an aggregate gross sales price of up to $30,000,000 through Wainwright, acting as sales agent or principal, pursuant to this prospectus supplement and the accompanying prospectus.